VALENZABIO
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases. ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.
VALENZABIO
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2019-01-01
Address:
Bethesda, Maryland, United States
Country:
United States
Website Url:
http://www.valenzabiotech.com
Total Employee:
1+
Status:
Active
Contact:
212 945 8929
Total Funding:
93.87 M USD
Technology used in webpage:
Cloudflare Hosting
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Inmagene Biopharmaceuticals
It is a leading biotech company focused on immunology-related therapeutic areas.
Current Employees Featured
Founder
Investors List
Pierre Fabre
Pierre Fabre investment in Series A - ValenzaBio
Ikarian Capital
Ikarian Capital investment in Series A - ValenzaBio
Fidelity
Fidelity investment in Series A - ValenzaBio
Surveyor Capital
Surveyor Capital investment in Series A - ValenzaBio
Opaleye Management
Opaleye Management investment in Series A - ValenzaBio
Janus Henderson Investors
Janus Henderson Investors investment in Series A - ValenzaBio
Official Site Inspections
http://www.valenzabiotech.com
Unable to get host informations!!!
More informations about "ValenzaBio"
ValenzaBio - Crunchbase Company Profile & Funding
ValenzaBio is located in Bethesda, Maryland, United States. Who invested in ValenzaBio? ValenzaBio has 6 investors including Pierre Fabre and Ikarian Capital. How much funding has …See details»
ValenzaBio Company Profile 2024: Valuation, Investors ... - PitchBook
ValenzaBio is headquartered in Bethesda, MD. What is the size of ValenzaBio? ValenzaBio has 10 total employees. What industry is ValenzaBio in? ValenzaBio’s primary industry is Drug …See details»
ValenzaBio Company Profile | Management and Employees List
ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting …See details»
Valenza Biotech - Products, Competitors, Financials, Employees ...
ValenzaBio is a biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting …See details»
ValenzaBio Inc - Company Profile and News - Bloomberg Markets
ValenzaBio, Inc. operates as a biopharmaceutical company. The Company specializes in developing therapies for autoimmune and inflammatory diseases. ValenzaBio serves medical …See details»
ACELYRIN acquires ValenzaBio, strengthens immunology position
3 days ago · ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately …See details»
ValenzaBio - VentureRadar
Website: https://www.valenzabiotech.com/ Develops clinical-stage biopharmaceutical therapies targeting cell surface receptors for autoimmune and inflammatory diseases using monoclonal …See details»
ValenzaBio Announces Positive Preliminary Data from ... - Business …
Nov 3, 2022 · BETHESDA, Md.-- (BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and …See details»
ValenzaBio Announces FDA Clearance of Investigational New Drug ...
Mar 31, 2022 · VB421 is a potential best-in-class mAb targeting IGF-1R, which plays a central role in the pathogenesis of TED. “We are excited to have received FDA clearance of our IND …See details»
ValenzaBio Advances Pipeline of Antibody Therapeutics Toward …
Apr 8, 2021 · VB421, a potential best-in-class anti-IGF-1R antibody, which ValenzaBio has licensed from Pierre Fabre and plans to evaluate for the treatment of thyroid eye disease …See details»
Valenza Biotech - Company Profile - Tracxn
Oct 26, 2024 · Valenza Biotech has raised a total funding of $14.5M over 1 round. Access funding benchmarks and valuations. Sign up today! Who are Valenza Biotech's investors? There are …See details»
Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal
Jan 5, 2023 · Acelyrin Inc., a biotechnology company backed with more than $550 million in venture capital, has acquired drug startup ValenzaBio Inc. to boost its pipeline of potential …See details»
Valenza Biotech - Overview, News & Similar companies - ZoomInfo
View Valenza Biotech (www.valenzabio.com) location , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
License and Commercialization agreement between Pierre Fabre …
ValenzaBio is a privately held biopharmaceutical company focused on developing safe and effective therapies for autoimmune and inflammatory diseases.See details»
ValenzaBio Announces Positive Preliminary Data from Phase 1b
Nov 3, 2022 · ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced positive …See details»
ValenzaBio and Novelty Nobility Announce Exclusive ... - Business …
Feb 15, 2022 · VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. …See details»
ValenzaBio Selects Ready by ArcheMedX to Expedite Biomarker …
Apr 21, 2021 · ValenzaBio is deploying Ready to transform the critical phases of study start-up and on-going site engagement for their VB119 study.See details»
ValenzaBio Advances Pipeline of Antibody Therapeutics Toward …
Apr 8, 2021 · ValenzaBio is a privately held biopharmaceutical company focused on developing safe and effective therapies for autoimmune and inflammatory diseases.See details»
ACELYRIN | Accelerating Life-Changing Medicines
Nov 13, 2024 · Building a sustainable biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines.See details»
ValenzaBio advances pipeline of antibody therapeutics
Apr 8, 2021 · ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, today announced the completion of …See details»